1-3 of 3
Michael Sandherr, MD
Close
Sort by
Journal Articles

Bendamustine Plus Rituximab Versus Fludarabine Plus Rituximab In Patients with Relapsed Follicular, Indolent and Mantle Cell Lymphomas – Final Results of the Randomized Phase III Study NHL 2–2003 on Behalf of the StiL (Study Group Indolent Lymphomas, Germany)

Mathias J Rummel, MD, PhD, Ulrich Kaiser, MD, Christina Balser, Martina Beate Stauch, Wolfram Brugger, MD, PhD, Manfred Welslau, Norbert Niederle, Christoph Losem, Harald Ballo, Eckhart Weidmann, Ulrich von Gruenhagen, Lothar Mueller, Michael Sandherr, MD, Julia Vereschagina, Axel Hinke, Juergen Barth
Journal: Blood
Blood (2010) 116 (21): 856.
https://doi.org/10.1182/blood.V116.21.856.856
Published: 2010
Journal Articles

Y-90 Ibritumomab Tiuxetan as Consolidation Following Three Cycles of Fludarabine-Cyclophosphamide-Rituximab Chemoimmunotherapy in Patients with Relapsed Follicular, Indolent or Mantle-Cell Lymphoma: A Prospective “Dose”-Finding Study.

Christoph von Schilling, MD, Kathleen Schwarz, MD, Georg Hess, MD., Ph.D., Andreas Viardot, MD, Michael Sandherr, MD, Stefan Krause, MD., Ph.D., Jan P. Simon, MD, Ph.D., Nadine Roethling, Christian Peschel, MD, Ph.D., Markus Schwaiger, MD, Ph.D., Klemens Scheidhauer, MD, Ph.D.
Journal: Blood
Blood (2007) 110 (11): 3426.
https://doi.org/10.1182/blood.V110.11.3426.3426
Published: 2007
Journal Articles

Antifungal Prophylaxis with Itraconazole in Patients with Acute Leukemia and after Stem Cell Transplantation (SZT): High Plasma Concentrations with a Loading Dose Strategy.

Michael Sandherr, MD, Michael Vogeser, MD, Carsten Hartig, MD, Christoph Aulmann, MD, Stefanie Fuhrmann, MD, Linda Wondzinski, MD, Daniel Oruzio, MD, Guenter Schlimok, MD
Journal: Blood
Blood (2004) 104 (11): 5062.
https://doi.org/10.1182/blood.V104.11.5062.5062
Published: 2004